Centessa Pharmaceuticals plc (CNTA)
Largest Insider Buys in Sector
CNTA Stock Price History Chart
CNTA Stock Performance
About Centessa Pharmaceuticals plc
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of …
Insider Activity of Centessa Pharmaceuticals plc
Over the last 12 months, insiders at Centessa Pharmaceuticals plc have bought $0 and sold $14.08M worth of Centessa Pharmaceuticals plc stock.
On average, over the past 5 years, insiders at Centessa Pharmaceuticals plc have bought $75.13M and sold $5.23M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,000 shares for transaction amount of $92,568 was made by SAHA SAURABH (Chief Executive Officer) on 2022‑06‑24.
List of Insider Buy and Sell Transactions, Centessa Pharmaceuticals plc
| 2024-12-20 | Sale | Chief Executive Officer | 55,000 0.0422% | $17.44 | $959,057 | +1.28% | ||
| 2024-12-17 | Sale | Chief Technology & Quality Ofc | 17,813 0.0138% | $18.00 | $320,634 | -2.50% | ||
| 2024-12-17 | Sale | Chief People Officer | 10,624 0.0079% | $17.32 | $184,036 | -2.50% | ||
| 2024-12-16 | Sale | Chief Technology & Quality Ofc | 9,611 0.0072% | $16.36 | $157,256 | +3.76% | ||
| 2024-12-16 | Sale | General Counsel | 77,705 0.0585% | $16.39 | $1.27M | +3.76% | ||
| 2024-12-13 | Sale | Chief People Officer | 5,876 0.0045% | $17.01 | $99,974 | +3.56% | ||
| 2024-12-06 | Sale | Chief Executive Officer | 87,496 0.0665% | $18.46 | $1.62M | -8.41% | ||
| 2024-11-25 | Sale | Chief Executive Officer | 299 0.0002% | $18.23 | $5,451 | +0.41% | ||
| 2024-11-25 | Sale | Chief Business Officer | 10,000 0.0079% | $17.66 | $176,601 | +0.41% | ||
| 2024-11-22 | Sale | Chief Executive Officer | 1,671 0.0015% | $18.24 | $30,478 | +0.70% | ||
| 2024-11-21 | Sale | Chief Executive Officer | 3,511 0.0027% | $18.24 | $64,028 | -5.66% | ||
| 2024-11-20 | Sale | Chief Executive Officer | 55,000 0.0424% | $16.89 | $928,719 | +2.51% | ||
| 2024-11-13 | Sale | Chief Executive Officer | 32,023 0.0284% | $18.28 | $585,419 | -5.09% | ||
| 2024-10-25 | Sale | Chief Business Officer | 11,742 0.0103% | $15.38 | $180,628 | 0.00% | ||
| 2024-10-23 | Sale | Chief Executive Officer | 2,592 0.0023% | $15.32 | $39,697 | 0.00% | ||
| 2024-10-22 | Sale | Chief Executive Officer | 30,203 0.027% | $15.67 | $473,169 | 0.00% | ||
| 2024-10-21 | Sale | Chief Executive Officer | 22,205 0.0196% | $15.80 | $350,861 | +7.79% | ||
| 2024-09-25 | Sale | Chief Business Officer | 16,619 0.0148% | $15.69 | $260,724 | -0.12% | ||
| 2024-09-20 | Sale | Chief Executive Officer | 55,000 0.0484% | $16.53 | $908,985 | -0.27% | ||
| 2024-09-10 | Sale | Chief Executive Officer | 175,000 0.1752% | $16.52 | $2.89M | +12.89% |
Insider Historical Profitability
| SAHA SAURABH | Chief Executive Officer | 520661 0.3955% | $17.66 | 3 | 16 | <0.0001% |
| Weinhoff Gregory M | Chief Business Officer | 183266 0.1392% | $17.66 | 1 | 9 | <0.0001% |
| Bush Tia L | Chief Technology & Quality Ofc | 147615 0.1121% | $17.66 | 2 | 5 | <0.0001% |
| HUSSAIN IQBAL J | General Counsel | 125785 0.0955% | $17.66 | 1 | 3 | <0.0001% |
| GAP (Bermuda) LTD | 10 percent owner | 9681818 7.3537% | $17.66 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Medicxi Growth I Lp | $225.58M | 17.66 | 19.96M | 0% | +$0 | 50.22 | |
| General Atlantic | $109.4M | 8.57 | 9.68M | 0% | +$0 | 2.84 | |
| Ecor1 Capital Llc | $63.49M | 4.97 | 5.62M | 0% | +$0 | 0.45 | |
| Vida Ventures Advisors Llc | $44.43M | 3.48 | 3.93M | 0% | +$0 | 24.68 | |
| Perceptive Advisors | $34.84M | 2.73 | 3.08M | New | +$34.84M | 0.02 |